Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
ATAI Life Sciences (ATAI)
NASDAQ:ATAI
ATAI Life Sciences (ATAI) Stock Price & Analysis
803 Followers
ATAI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.03 - $2.85
Previous Close$1.35
Volume539.23K
Average Volume (3M)1.32M
Market Cap
$226.00M
Enterprise Value$198.36M
Total Cash (Recent Filing)$45.03M
Total Debt (Recent Filing)$16.04M
Price to Earnings (P/E)―
Beta1.44
Next Earnings
Aug 12, 2024EPS Estimate
-$0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding167,406,070
10 Day Avg. Volume901,134
30 Day Avg. Volume1,318,138
Standard Deviation0.17
R-Squared0.06
Alpha-0.06
Financial Highlights & Ratios
Price to Book (P/B)0.92
Price to Sales (P/S)12462.45
Price to Cash Flow (P/CF)-2.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue631.70
Enterprise Value/Gross Profit631.70
Enterprise Value/Ebitda-5.32
Forecast
1Y Price Target
$9.75Price Target Upside650.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
ATAI Life Sciences News
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentsInitial data show that a single dose of BPL-003 led to a rapid onset of psychedelic effects and durable antidepressant effect in 55% of patients on the day after dosing.
Financial StabilityOperating expenses came in lighter than anticipated, which could be due to the company's reprioritized pipeline and cost-optimization initiatives.
Strategic InvestmentStrategic investment in Beckley cements atai's leadership in the psychedelic space.
Bears Say
Clinical DevelopmentEnrollment for RL-007 is taking longer than expected, which may delay the top-line data release.
Financial Performance1Q24 total net loss was $26.7MM.
Market CompetitionKeep a watch on developments from competitor GHRS.
---
Ownership Overview
33.68% Insiders
0.65% Mutual Funds
2.37% Other Institutional Investors
63.29% Public Companies and Individual Investors
ATAI FAQ
What was ATAI Life Sciences’s price range in the past 12 months?
ATAI Life Sciences lowest stock price was $1.02 and its highest was $2.85 in the past 12 months.
What is ATAI Life Sciences’s market cap?
Currently, no data Available
When is ATAI Life Sciences’s upcoming earnings report date?
ATAI Life Sciences’s upcoming earnings report date is Aug 12, 2024 which is in 41 days.
How were ATAI Life Sciences’s earnings last quarter?
ATAI Life Sciences released its earnings results on May 13, 2024. The company reported -$0.17 earnings per share for the quarter, beating the consensus estimate of -$0.182 by $0.012.
Is ATAI Life Sciences overvalued?
According to Wall Street analysts ATAI Life Sciences’s price is currently Undervalued.
Does ATAI Life Sciences pay dividends?
ATAI Life Sciences does not currently pay dividends.
What is ATAI Life Sciences’s EPS estimate?
ATAI Life Sciences’s EPS estimate is -$0.17.
How many shares outstanding does ATAI Life Sciences have?
ATAI Life Sciences has 167,406,070 shares outstanding.
What happened to ATAI Life Sciences’s price movement after its last earnings report?
ATAI Life Sciences reported an EPS of -$0.17 in its last earnings report, beating expectations of -$0.182. Following the earnings report the stock price went up 2.646%.
Which hedge fund is a major shareholder of ATAI Life Sciences?
Among the largest hedge funds holding ATAI Life Sciences’s share is Lumina Fund Management Llc. It holds ATAI Life Sciences’s shares valued at N/A.
---
ATAI Life Sciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.75 (650.00% Upside)
$9.75 (650.00% Upside)
Blogger Sentiment
Bullish
ATAI Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 17.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $521.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.5%
Last 30 Days ▲ 1.9%
Last 30 Days ▲ 1.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-21.51%
12-Months-Change
Fundamentals
Return on Equity
-14.72%
Trailing 12-Months
Asset Growth
-4.13%
Trailing 12-Months
Company Description
ATAI Life Sciences
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine.
---
ATAI Stock 12 Month Forecast
Average Price Target
$9.75
▲(650.00% Upside)
Technical Analysis
Best Analysts Covering ATAI
1 Year
1 Year Success Rate
3/20 ratings generated profit
1 Year Average Return
-35.41%
reiterated a buy rating 2 months ago
Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 15.00% of your transactions generating a profit, with an average return of -35.41% per trade.
---